Kos to Report Second Quarter Results on August 8, 2006 Conference Call at 8:30 a.m. ET

Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully
integrated specialty pharmaceutical company, will announce results for
the second quarter ended June 30, 2006, before the market opens on
Tuesday, August 8, 2006.
   Following the release, Kos' senior management will host a
conference call at 8:30 a.m. ET to discuss the Company's results. The
conference call will be available live via the Internet by accessing
Kos' website at www.kospharm.com. Please go to the website at least
fifteen minutes prior to the call to register, download and install
any necessary audio software. Those who cannot access the webcast can
dial into the conference call at 913-981-4911 confirmation code
6754547. A replay will also be available on the website at
www.kospharm.com or by calling 888-203-1112 domestic or international,
and entering 6754547 from 2:00 PM ET on August 8, 2006 until 12:00 AM
ET on August 15, 2006.
   If you would like to receive notices and news regarding Kos,
please visit the Investor Relations section of the Company website and
subscribe to email alerts.
   Kos Pharmaceuticals, Inc. is a fully integrated specialty
pharmaceutical company engaged in developing, commercializing,
manufacturing and marketing proprietary prescription products for the
treatment of chronic diseases with a particular focus on the
cardiovascular, metabolic and respiratory disease areas. The Company's
principal product development strategy is to reformulate existing
pharmaceutical products with large market potential to improve safety,
efficacy, and patient compliance. Kos' strategy also includes making
measured investments in new chemical entity research through in-house
and sponsored research, scientific in-licensing and general corporate
development activities. The Company currently markets Niaspan(R),
Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT.
Kos has a strong and growing research and development pipeline
including proprietary drug delivery technologies in solid-dose,
inhalation and aerosol metered-dose device administration to help fuel
sustained, organic sales growth into the future.

   Certain statements in this press release, including statements
relating to the Company's strong and growing research and development
pipeline and future sales growth are forward-looking and are subject
to risks and uncertainties which may cause actual results to differ
materially from those projected in a forward-looking statement. These
risks and uncertainties include the Company's ability to successfully
develop and commercialize new products under development, the
Company's ability to enter into new business development and corporate
opportunities, the progress of the company's research and development
pipeline, the protection afforded by the Company's patents, the effect
of conditions in the pharmaceutical industry and the economy in
general, and the Company's ability to maintain compliance with FDA. A
more detailed discussion of risks attendant to the forward-looking
statements included in this press release are set forth in the
"Forward-Looking information: Certain Cautionary Statements" section
of the Company's Annual Report on Form 10-K for the year ended
December 31, 2005, filed with the Securities and Exchange Commission,
and in other reports filed with the SEC.